logo

For the Inventor, By the Inventor

Waltham, MA, United States of America

Cody A Desjardins

USPTO Granted Patents = 32 

Average Co-Inventor Count = 5.4

ph-index = 15

Forward Citations = 519(Granted Patents)


Company Filing History:

goldMedal32 out of 52 
 
Dyne Therapeutics, Inc.
 patents

Years Active: 2023-2025

Loading Chart...
32 patents (USPTO):Explore Patents
1. 12460011 - Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering an oligonucleotide to a subject (2025-11-04),
2. 12440575 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-10-14),
3. 12440574 - Muscle targeting complexes and formulations for treating myotonic dystrophy (2025-10-14),
4. 12428487 - Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject (2025-09-30),
5. 12403203 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-09-02),
6. 12397062 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-08-26),
7. 12370264 - Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject (2025-07-29),
8. 12329824 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-06-17),
9. 12319743 - Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject (2025-06-03),
10. 12280122 - Muscle targeting complexes and uses thereof for treating myotonic dystrophy (2025-04-21),
11. 12239717 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-03-04),
12. 12239716 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-03-04),
13. 12173078 - Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide (2024-12-24),
14. 12144868 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2024-11-19),
15. 12144867 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2024-11-19),

Title: Cody A. Desjardins: Innovator in Molecular Treatment for Dystrophinopathies

Introduction

Cody A. Desjardins is an accomplished inventor based in Waltham, Massachusetts, with a notable portfolio comprising 22 patents. His contributions to the field of molecular therapeutics have significantly impacted the treatment of dystrophinopathies, diseases that affect muscle function due to issues with the dystrophin protein.

Latest Patents

Among his latest inventions is a groundbreaking patent focused on muscle-targeting complexes designed for the treatment of dystrophinopathies. This innovation involves complexes that combine a muscle-targeting agent, which covalently links to a molecular payload. The muscle-targeting agent specifically binds to receptors on muscle cells, ensuring an effective delivery system. The molecular payload is designed to enhance the expression or functionality of a functional dystrophin protein, utilizing oligonucleotides such as antisense oligonucleotides that promote exon skipping in mRNA from a mutant DMD allele.

Career Highlights

Cody currently works at Dyne Therapeutics, Inc., where he applies his expertise in molecular therapies to advance treatment options for those suffering from muscle diseases. With 22 patents to his name, his career reflects a commitment to innovation and improvement in therapeutic practices.

Collaborations

Throughout his career, Cody has collaborated with talented professionals including Mohammed T. Qatanani and Timothy Weeden. These partnerships highlight the importance of teamwork in the research and development of cutting-edge treatments.

Conclusion

Cody A. Desjardins represents the forefront of innovation in molecular treatment for dystrophinopathies. His extensive patent portfolio and collaborative spirit illustrate his dedication to improving patient outcomes and advancing scientific knowledge in the field of muscle-targeting therapies. As he continues to develop new solutions, his work will undoubtedly pave the way for future breakthroughs in the treatment of muscular diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…